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ABSTRACT
The American University in Cairo
Overexpression of Cofactor of BRCA1 in HepG2 Cells: A Step Towards
Understanding the Role of COBRA1 in Hepatocellular Carcinoma
By Razan Jamil Masad
Under the supervision of Dr. Asma Amleh
Cofactor of BRCA1 (COBRA1) is a BRCA-1 interacting protein that represents one of
the four subunits of the negative elongation factor (NELF) complex. NELF is known
by its ability to stall RNA Polymerase II during the early phase of transcription
elongation, resulting in repressed transcription of several genes including ones
associated with tumorigenesis of different cancer types. While it was found to be downregulated in breast cancer, COBRA1 was found to be up-regulated in the upper
gastrointestinal carcinoma. Up to date, the role of COBRA1 in hepatocellular
carcinoma (HCC) is unclear. We have previously demonstrated that silencing of
COBRA1 in the HCC cell line HepG2, significantly inhibited the proliferation and
migration potentials of the cells. Here, we investigated the effect of ectopic expression
of COBRA1 on HepG2 cells proliferation and migration. Lipofectamine 3000 was used
to transfect HepG2 cells with a pCMV5-HCOBRA1 plasmid. The transfection
efficiency was determined by the percentage of EGFP positive cells (pEGFP-N1+) via
fluorescent microscope, semi-quantitative RT-PCR as well as western blot analysis.
The cells proliferation and migration following COBRA1 overexpression were
assessed using the trypan blue dye exclusion method and the wound-healing assays
respectively. The semi-quantitative RT-PCR was used to analyse the mRNA
expressions of the other NELF subunits, TFF1 and TFF3 genes, which are known to be
regulated by the NELF complex, as well as other tumorigenesis related genes. Our
results revealed that COBRA1 transfected cells exhibited a comparable proliferation
and migration rates to non-transfected cells. These results were accompanied by an
insignificant effect of COBRA1 overexpression on the levels of the proliferation
marker; Ki-67 and the anti-apoptotic gene; survivin. Also, the mRNA levels of the other
NELF subunits, TFF1 and TFF3 were found to be comparable among all the tested
groups. Collectively, our results suggest that the proposed involvement of COBRA1 in
HCC is supported by and dependent on the assembly of the active NELF complex,
which requires the expression of all four NELF subunits. Moreover, COBRA1
mediated role in HCC tumorigenesis might be due to mechanisms and regulatory
pathways other than the ones examined here. However, further studies are required to
confirm these notions.
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CHAPTER 1. LITERATURE REVIEW

1.1. Hepatocellular Carcinoma
1.1.1 Incidence and epidemiology
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer,
accounting for more than 90% of primary liver cancer cases (Bodzin & Busuttil, 2015;
Liver, 2012). Currently, HCC ranks the sixth most frequent cancer and the second
leading cause of cancer-related deaths worldwide, where almost 746000 people die
from HCC each year(Ashtari, Pourhoseingholi, Sharifian, & Zali, 2015; Flores &
Marrero, 2014).
The frequency of HCC increases with age. In fact, most of the reported cases are
diagnosed at the age of 65 years or more (Waghray, Murali, & Menon, 2015). Having
a three times higher incidence rate in men than in women, HCC is considered a male
predominant cancer (Howlader, Noone, & Krapcho, 2015).
An extensive variation in the world-wide distribution of HCC has been remarkably
observed. While 3 out of 100 000 are infected with HCC in the western countries, more
than 15 out of 100,000 are infected in other regions of the world, most of which are
noticed in the developing countries (Siegel, Miller, & Jemal, 2015). In Egypt, HCC
incidence is very high compared to other countries. According to the MECC (Middle
East Cancer Consortium), HCC rate among Egyptian men was 7 times higher than other
MECC countries (Cyprus, Palestine & Jordan) and 3 times higher than the US SEER
(Surveillance, Epidemiology and End results populations). Among females, however,
HCC rate was 3 times higher than other MECC countries and more than twice the US
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SEER rate (Freedman, Edwards, Ries, & Young, 2006). The high occurrence of HCC
in Egypt is due to the high number of HCV infections, where almost 14% of the
Egyptian population is HCV-infected(Gomaa, Hashim, & Waked, 2014; Shelbaya,
Kuznik, Salem, Mankola, & Sadik, 2015)
1.1.2 Risk factors and prevention
Several factors have been reported to be involved in HCC development. These
factors include; liver cirrhosis, chronic hepatitis B virus (HBV) infection, chronic
hepatitis C virus (HCV) infection, hereditary hemochromatosis, aflatoxin consumption,
alcoholism, diabetes as well as obesity (Flemming, Yang, Vittinghoff, Kim, & Terrault,
2014).
Being presented in almost (80-90%) of HCC-infected individuals, liver cirrhosis is
considered as the main risk factor for HCC (El-Serag, 2012a). Mainly, liver cirrhosis
results from viral hepatitis infection, Alcohol-related liver disease, Nonalcoholic fatty
liver disease (NAFLD) as well as aflatoxin consumption (Flemming et al., 2014).
Despite the wide regional variations in HCC etiology and distribution, chronic
infections with hepatitis B and C represent the majority of HCC cases globally (ElSerag, 2012a). HBV infection results in acute and chronic liver disease, increasing by
this the risk of developing HCC(El-Serag, 2012a). Several mechanisms for the
progression from HBV to HCC have been proposed. For instance, both the
inflammation and necrosis that result from HBV may cause alterations in the
hepatocyte’s genetic expressions, resulting in induction of the malignancy(Rossner,
1992). In addition, viral integration in to the liver cells results in a chromosomal
instability and defected cellular replication leading to the development of
HCC(Brechot, Pourcel, Louise, Rain, & Tiollais, 1980; Kremsdorf, Soussan, PaterliniBrechot, & Brechot, 2006).
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Upon introducing the obligatory universal HBV vaccination at birth, a decline of the
HBV-related HCC cases was observed. For instance, following implementation of the
Taiwan universal vaccination program, a significant reduction in the HCC annual
incidence from 0.70 to 0.36 per 100,000 children was reported within a 10-year period
(Ni et al., 2007). However, since this mandatory vaccination was implemented in the
early 1980s, most of the adults over the age of 30 are not vaccinated and are at high
risk of developing HCC(Pol, 2015). Thus, HBV prevention among adults is carried out
through focusing on anti-viral treatments such as interferon alpha (IFN-a). In fact, IFNa was shown to decrease the risk of developing HCC by a percentage of 6.4% (Cammà,
Giunta, Andreone, & Craxı,̀ 2001).
HCV infection leads to an inflammatory hepatocyte damage from oxidative stress,
indorsing by this liver cirrhosis and resulting in HCC development (Parola & Robino,
2001). Currently, almost 40-50% of HCC cases are attributed to chronic HCV
infections (Bruix & Sherman, 2005; Omar, Abou-Alfa, Khairy, & Omar, 2013). In fact,
HCV-infected individuals have 17-times higher risk of developing HCC compared to
HCV-negative individuals (Tanaka et al., 2006). Usually, HCV antiviral treatments are
used to decrease the risk of the development of HCV-based HCC. Many studies have
shown that responders to treatment with interferon (IFN) have a lower risk of
developing HCC compared to non-responders and not-treated patients (Yoshida et al.,
1999).
Alcohol related liver disease and Nonalcoholic fatty liver disease (NAFLD) also
contributes to the development of HCC(Waghray et al., 2015). The molecular strategy
by which alcoholism leads to HCC is not well addressed. However, several evidences
indicate that it might be through indorsing altered DNA methylation, reduction in the
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liver’s retinoic acid level, oxidative stress as well as chromosomal loss (Bruix, Gores,
& Mazzaferro, 2014).
NAFLD incidence is increasing due to the increasing numbers of obesity and
diabetes worldwide. NAFLD is characterized by the fatty livers of infected individuals
as well as inflammation and fibrosis(Petta et al., 2015; Pinzani, 2015). Almost 40% of
NAFLD patients develop fibrosis, in which 9% of them progress to cirrhosis, resulting
in the development of HCC as a complication (Adams et al., 2005; J. M. Hui et al.,
2003).
Alfatoxin-B1 consumption is also considered as one of the major contributors to
HCC development. Aflatoxins are mycotoxins produced by the Aspergillus fungus and
Aspergillus parasiticus. They are mostly found on improperly stored food including
rice, corn, peanuts and wheat (El-Serag, 2012a). The ability of aflatoxins to induce
hepatocarcinogenesis was shown in several animal experiments. One study has
revealed that when ingested, aflatoxin metabolizes to an active aflatoxin B1-exo-8, 9epoxide. As a result, it binds to the DNA and causes DNA damage. This eventually
results in the development of mutations in the tumor suppressor gene p53 (p53 249 ser),
which will in turn induce the development of HCC (Garner, Miller, & Miller, 1972).
In fact, these mutations have been observed in almost 30-60 % of HCC patients in
aflatoxin-endemic regions (TURNER et al., 2002). In Egypt, Aflatoxin B1
consumption is considered as one of the main risk factors of HCC development (Omar
et al., 2013).
Both obesity and diabetes are common risk factors of HCC. In fact, obese patients
are100-times at risk of developing HCC than non-obese patients (Chen et al., 2008).
Likewise, Diabetes is related to a 2-3 fold increase in the risk of developing HCC(J.
Davila, Morgan, Shaib, McGlynn, & El-Serag, 2005).
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Other less common risk factors for HCC development include; Wilson’s disease,
glycogen storage disease, autoimmune hepatitis, hereditary hemochromatosis and
alpha 1-anti trypsin deficiency (Waghray et al., 2015).
1.1.3 Surveillance and diagnosis
HCC patients diagnosed at early stages have higher survival rates compared to those
diagnosed with advanced stages (Bruix & Llovet, 2009). Therefore, standardized
surveillance is recommended for patients at risk of HCC development. Surveillance
involves a repeated screening of patients at high risk of HCC. The effectiveness of
surveillance depends on the incidence of HCC in the target population as well as the
availability of effective diagnostic tests and treatments (Verslype, Rosmorduc,
Rougier, & Group, 2012).
Previous studies have indicated that surveillance increases the survival when the
yearly rate of HCC is more than 1.5% of the target population (Sarasin, Giostra, &
Hadengue, 1996). According to the guidelines indorsed by the American association
for the study of liver diseases (AASLD) and the European society for medical oncology
(ESMO), HCC Surveillance includes a mandatory abdominal ultrasound screening
every 6 months (El-Serag, 2012b; Verslype et al., 2012).
1.1.4 Staging and therapeutic management
Currently, there are several treatment options available for HCC patients. These
treatments could be either curative or palliative. The curative treatment options include;
liver transplantation, surgical resection and local ablation. These options have shown a
5-year survival rates of up to 75% (El-Serag, Marrero, Rudolph, & Reddy, 2008; Lin,
Hoffmann, & Schemmer, 2012). Nonetheless, due to the small number of eligible
patients to such treatments (less than 20%), most of the patients are exposed to
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palliative treatments such as transarterial chemoembolization as well as chemotherapy
(Clark et al., 2005; J. A. Davila, Duan, McGlynn, & El-Serag, 2012).
The choice of the optimal therapy is decided according to the tumour stage.
Currently, several staging systems have been developed to assess the stage of HCC.
Both the Child-Pugh system and the model for end-stage liver disease (MELD) are
used to evaluate the disease’s severity without dealing with the patient’s symptoms or
performance (Bruix & Sherman, 2011; Jelic, Sotiropoulos, & Group, 2010).
The Barcelona Clinic Liver Cancer (BCLC) staging system aims to link the disease
stage with the patient’s performance, and it is the best to be used for selection of the
proper therapy for HCC patients (Bruix & Sherman, 2011; J. Llovet & Ducreux, 2012).
Usually, this system is used to identify patients with early-stage HCC (stage 0 and A)
who are suitable for curative therapies, patients at intermediate or advanced stages
(stages B&C) who are suitable for palliative treatments as well as patients with stage
D HCC who have a very poor life expectancy (Lencioni, Chen, Dagher, & Venook,
2010).
Liver transplantation (LT) is the best possible curative treatment choice for HCC as
well as the underlying cirrhosis(de Lope, Tremosini, Forner, Reig, & Bruix, 2012). It
was shown that liver transplantation has resulted in a better overall survival rate
compared to other options (Waghray et al., 2015). Thus, HCC patients with
complicated cirrhosis should be assessed for their eligibility for such treatment. To
assess the patient’s eligibility to liver transplantation, three selection criteria are used
[Milan Criteria, University of California San Francisco (UCSF) and MELD
(Mazzaferro et al., 1996; Pelletier et al., 2009). According to the Milan criteria, patients
that have a single lesion( < 5 cm) or a maximum of 3 lesions (with each < 3cm), without
any metastasis or vascular invasion are good candidates for LT (Mazzaferro et al.,
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2011). Patients meeting these criteria have shown a 4-year overall survival rate of 85%
and a recurrence rate of less than12% (Kim & Hemming, 2009; Mazzaferro et al.,
2011).
In 2011, the UCSF criteria has expanded the eligibility requirements, and included
patients present with a single lesion (< 6.5 cm) or 3 lesions (with each one < 4.5 cm),
and a total tumor diameter that is equal to or less than 8 cm. This selection criterion has
shown comparable survival rates to the Milan criteria (Leung et al., 2004).
The MELD score system aims to prioritize the patient’s assignments to the LT
waiting list. Each HCC patient has a MELD score of 22 which increases every 3
months. The MELD score is able to expect the mortality rates among patients with
cirrhosis. However, due to its inability to predict the mortality rates among noncirrhotic HCC patients, an exception criteria was created to give extra points for HCC
patients. In fact, applying this criteria have resulted in a rise of the number of HCC
patients undergoing LT (Taniguchi, 2011).
Surgical resection is considered as the best treatment choice for early stage-HCC
patients having single lesions without any underlying cirrhosis (Vennarecci et al.,
2007). However, despite having a five-year survival rate of 70%, patients undergoing
surgical resection have a high recurrence risk. In fact, an early recurrence within two
years of surgery usually occurs due to an intrahepatic metastasis and local invasion.
(Cucchetti et al., 2009; Xia et al., 2010).
In the last decade, tumor ablation was used in treating HCC and has resulted in
highly satisfactory results. Radiofrequency ablation (RFA) is considered as the best
ablative therapy used for early stage HCC patients that are unsuitable for liver
transplantation nor surgical resection (Nishikawa, Kimura, Kita, & Osaki, 2013).
Patients with tumors of less than two cm diameter were reported to have the best results
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when treated with RFA. In fact, these patients showed 90% chance of complete ablation
upon receiving this treatment (Nishikawa et al., 2013).
Transarterial chemoembolization (TACE) is the best therapy choice for patients with
intermediate-stage HCC with a single lesion of less than 5 cm without any vascular
invasion or hepatic metastasis (Forner, Llovet, & Bruix, 2012). It is based on the
obstruction of blood supply to the tumor by introducing several chemotherapeutic
agents such as doxorubicin, cisplatin and epirubcin (Forner et al., 2012). TACE- based
therapy has resulted in a 25% decrease in tumor size in almost 40% of the patients(J.
M. Llovet & Bruix, 2003).
Systemic chemotherapy using cytotoxic drugs such as tamoxifen, cisplatin and
everolimus have shown low response rates (Verslype et al., 2012). In fact, until now,
Sorafinib was shown to be the only effective systemic therapy in advanced HCC
(Bolondi et al., 2015). Sorafinib is an oral multi kinase inhibitor that works by blocking
several cellular kinases involved in tumorigenesis such as vascular endothelial growth
factor (VEGF) receptors, platelet-derived growth factor receptors (PDGFRs), c-KIT
and RaslMAPK signalling pathways (S. Wilhelm et al., 2006; S. M. Wilhelm et al.,
2004). In a 2- phase III randomized placebo-controlled trials conducted in America,
Europe and Asia, Sorafinib was found to have an anti-proliferative, anti-angiogenic as
well as pro-apoptotic activity. In addition, using Sorafinib has resulted in 44% increase
in the overall survival and a 3 months increase in the median survival among HCC
patients (Cheng et al., 2009; J. M. Llovet et al., 2008).
1.1.5 Molecular alterations in HCC
Regardless of the availability of several surveillance and management tools of HCC,
the exact molecular pathogenesis behind HCC remains unclear (Aravalli, Steer, &
Cressman, 2008). Thus, research is focusing currently on identifying the key molecular
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mechanisms underlying the development of HCC with the hope of developing new
novel therapeutic strategies.
Several oncogenes and tumor suppressors involved in the cell cycle and apoptosis
are known to be associated with HCC development as a result of their mutations. p53
gene is the most commonly mutated gene in HCC, where it was found to be mutated at
advanced HCC stages compared to earlier ones (Oda, Tsuda, Sakamoto, & Hirohashi,
1994; Qin et al., 2002). The p16 (CDKN2A) tumor suppressor gene is known to be
involved in the cell cycle regulation, and was shown to be suppressed in HCC due to
its hypermethylation. Mainly, p16 suppression occurs more frequently in advanced
HCCs (40%) than in early HCC cases(A. Hui et al., 1996). Other HCC-associated
deregulated oncogenes and tumor suppressors include β-catenin, CTNNB1, ARID2,
ARID1A, MLL, ErbB family members and E-cadherin (Farazi & DePinho, 2006;
Fujimoto et al., 2012).
Deregulation of several signal transduction pathways also contributes to the
development of HCC. Among these signalling pathways is the Wnt/β-catenin,
RaslMAPK/EGFR,IGF and AKT/PKB(Guichard et al., 2012; Wong & Ng, 2008).
All of the above mentioned molecular alterations are more frequent in advanced
stages of HCC than in early stages. Thus, currently, the research is directed towards
identifying new molecular markers associated with early stages of HCC. Among these
are the heat-shock 70 (hsp70) and adenylate cyclase-associated protein 2(CAP2). In
fact, both these genes were found to be detected in early HCC stages in addition to their
high expression in advanced stages(Chuma et al., 2003; Shibata et al., 2006).
Other molecular markers detected in the blood are used for HCC diagnosis. Αlphafetoprotein (AFP) is the most commonly used HCC tumour marker (Debruyne &
Delanghe, 2008). Among its three forms (AFP-L1,AFP-L2 and AFP-L3), AFP-L3 has
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the highest sensitivity and specificity percentages in HCC detection (96.9%, 92%
respectively) (Hiraoka et al., 2015). In addition to AFP, Glypican-3 (GPC3),
Transforming growth factor-β1 (TGF-β1), Hepatoma-associated gene (HTA), AFP
mRNA and miRNAs were also described as crucial blood diagnostic markers of HCC.
(Liu et al., 2010; Lun, Ai-Qin, & Xuan, 2014; Zhi, Zhan, Deng, & Huang, 2007).
1.2. Cofactor of BRCA1
1.2.1 Identification, Structure and Function
Cofactor of BRCA1 (COBRA1) was first isolated from a human ovary cDNA
library and identified as a novel interacting protein with the breast cancer susceptibility
gene (BRCA1)(Ye et al., 2001). Previous studies have identified the role of BRCA1 in
regulating several nuclear processes such as transcription, recombination and DNA
repair (Chapman & Verma, 1996) (Lee, Collins, Brown, Lee, & Chung, 2000). These
nuclear functions are believed to be mediated by the chromatin de-condensation
activity of BRCA1, which occurs in the two BRCT domains required for interacting
with several transcription-regulatory factors such as p53, RNA helicase A and
CBP/p300 (Ye et al., 2001; Zhong et al., 2004).
In a study aiming to identify cofactors recruited by BRCA1 to mediate chromatin
de-condensation, a novel cofactor of BRCA1 (COBRA1) was identified and found to
be bound to the first chromatin de-condensation domain (BRCT) of BRCA1 (Ye et al.,
2001). The results of the study revealed that BRCA1-mediated chromatin decondensation is partially dependent on its recruitment of COBRA1. Remarkably,
COBRA1 was found to have a sufficient ability to induce a large scale of chromatin
de-condensation by itself. Moreover, BRCA1 mutations involved in the enhancement
of chromatin de-condensation were found to increase the affinity and recruitment of
BRCA1 to COBRA1 (Ye et al., 2001). These results indicated that chromatin
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remodelling is a significant step in both BRCA1 and COBRA1-mediated nuclear
activities.
COBRA1 encodes a 580-amino acid protein, in which 17% of its constituents are
rich in leucine residues(Ye et al., 2001). It contains three repeats of the LXXLL motif.
In fact, this motif is a main part of many transcription coactivators, due to its ability of
mediating the ligand-dependant interactions with several steroid hormone receptors
(Heery, Kalkhoven, Hoare, & Parker, 1997; Ye et al., 2001).
In 2003, COBRA1 was found to represent the β-subunit of the negative transcription
elongation factor complex (NELF), a 4-subunit complex that is known by its ability to
induce the stalling of RNA polymerase II during the early phase of transcription
elongation. The NELF complex is reported to regulate many genes known to be
involved in cellular mechanisms such as the cell cycle, differentiation, proliferation and
metabolism (Yamaguchi et al., 1999). The role of COBRA1 in early embryogenesis
was identified later through in vivo studies, where it was found that knocking out
COBRA1 in the mouse leads to early embryonic lethality (Amleh et al., 2009).
Having no DNA binding domain, COBRA1 could repress the transcription of its
target genes through interacting with other DNA-binding transcription factors such as
the remaining members of the NELF complex, AP1 complex, ERα as well as the
androgen receptor (AR)(S. E. Aiyar et al., 2004; J. Sun, Blair, Aiyar, & Li, 2007; Zhong
et al., 2004). This ability of COBRA1 to interact with different transcription complexes,
suggests its involvement in regulating different cellular processes including
transcription, gene expression and tumorigenesis. Below is an overview of some of the
main roles of COBRA1 in transcription regulation and tumorigenesis.
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1.2.2 COBRA1 role in transcription regulation
The transcription process (controlled by RNA polymerase II) is a crucial step by
which several genes and biological processes are controlled (Narita et al., 2003).
During the elongation phase, shortly after the transcription initiation, RNAPII escapes
from the promoter-proximal region and pauses 20-45 nucleotides downstream the
transcription start site, influencing by this, the efficiency of transcription and hindering
the transition to the productive elongation phase. This process is known as ‘promoter
proximal pausing or RNAPII stalling’, and was found to be associated with a wide
variety of biological systems (Adelman & Lis, 2012; Gilchrist et al., 2008; Narita et
al., 2003). The regulation of RNA stalling requires the involvement of negative and
positive transcription elongation factors.
DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) sensitivity-inducing factor
(DSIF) is a heterodimeric complex composed of p14 and p16. Along with the NELF
complex, it is responsible for the transcriptional pausing process (Narita et al., 2003;
Wada et al., 1998). Previous studies have revealed that DSFI doesn’t have an effect on
the catalytic activity of RNAPII upon binding to it (Yamaguchi et al., 1999). Similarly,
NELF doesn’t have a binding affinity to either DSIF or RNAPII alone. Instead, the
DSIF/RNAPII complex is required for such binding to occur. This association is
believed to activate the transcriptional pausing process(Yamaguchi, Inukai, Narita,
Wada, & Handa, 2002).
P-TEFB, a protein kinase composed of Cdk9 and one of the cyclin complexes T1,
T2a, T2b and K, is believed to reverse the transcription elongation inhibition by
preventing the action of both DSIF and NELF(Price, 2000; Yamaguchi et al., 1999). It
is believed that the kinase activity of P-TEFB is crucial for stimulating the
transcriptional elongation. Through phosphorylating the C-terminal domains of
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RNAPII (CTD), release of both DSIF and NELF from RNAPII is likely to occur. As a
result, the binding of 3’ elongation factors is facilitated, resulting in stimulation of the
elongation process (Bourgeois, Kim, Churcher, West, & Karn, 2002; Ping & Rana,
2001; Price, 2000).
Despite the involvement of the RNAPII stalling process in a variety of biological
mechanisms, at first, only few genes were reported to be regulated by this process such
as the mammalian proto-oncogene junB, Drosophila Hsp70, and HIV RNA(Wu et al.,
2005). The fact that only few genes were associated with the RNA stalling process has
led many to view it as a rare phenomenon. However, a genome-wide analysis of
Drosophila genes has changed this view by identifying more than 18000 Drosophila
genes associated with RNA stalling in their promoter regions(Muse et al., 2007;
Zeitlinger et al., 2007). Similarly, a study of RNAPII distribution in human cells has
identified the importance of the RNA stalling step in regulating the expression of many
genes known to have a role in the development (Guenther, Levine, Boyer, Jaenisch, &
Young, 2007; Muse et al., 2007; Zeitlinger et al., 2007).
All of these studies have increased the interest into understanding and identifying
the mechanisms by which the RNAPII stalling process is regulated. In a microarray
analysis of NELF regulated genes in drosophila, NELF was found to affect the
expression of many genes involved in a variety of cellular processes (Gilchrist et al.,
2008). Unexpectedly, most of the target genes have shown reduced levels upon NELF
knockdown, suggesting a role of NELF-dependent RNA stalling in enhancing the gene
expression in addition to suppressing it. This observation was explained by the ability
of the RNA stalling process of sustaining the chromatin architecture at the promoters
regions of these genes (Gilchrist et al., 2008).
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1.2.3 COBRA1 interaction with other transcription factors
Having no DNA binding domain, COBRA1 could repress the transcription of its
target genes through interacting with other DNA-binding transcription factors such as
the remaining members of the NELF complex, the Estrogen receptor α (ERα), the
Androgen receptor (AR) as well as the activator protein-1 (AP-1) complex (S. E. Aiyar
et al., 2004; J. Sun et al., 2007; Zhong et al., 2004).
In 2003, COBRA1 was found to represent the β-subunit of the negative
transcription elongation factor complex (NELF)(Narita et al., 2003). The negative
elongation factor (NELF) is a transcription regulatory complex that was identified by
its ability to induce stalling of RNA polymerase II (RNAPII) with the assistance of the
DRB sensitivity-inducing factor (DSIF) during the early phase of transcription
elongation (Yamaguchi et al., 1999).
The NELF complex consists of four subunits; NELF-A (66kDa), NELF-B (62kDa)
NELF-C/D (60kDa) and NELF-E (46kDa). NELF-A gene (WHSC2), which was
identified as a potential participant in the Wolf-Hirschhorn syndrome, contains an RNA
polymerase II binding domain, through which the NELF complex binds to RNA
polymerase II. NELF E, which has an RNA recognition domain, is responsible for
binding to the emerging RNAs arising from polymerase II. NELF-C/D, which are
homologous to the TH1-like mammalian protein, are believed to arise from a common
mRNA through alternative usage of translation initiation codons. Hence, either a C or
a D subunit is present in the NELF complex (Gilchrist et al., 2008; Narita et al., 2003).
Along with the NELF B subunit (COBRA1), all of these subunits are required for
the assembly of a functional NELF complex. In fact, several studies have identified the
interdependent manner by which the NELF subunits are regulated, where it was

14

reported that a depletion in one of these subunits results in a similar effect on the
remaining subunits (Narita et al., 2003; J. Sun et al., 2008).
Both Estrogen receptor α (ERα) and androgen receptor (AR) are DNA-binding
transcription factors that belong to the steroid hormone receptor family. These factors
are believed to control the transcription of genes by either a ligand-dependent or
independent means (Nilsson et al., 2001). The strength of such a transcription process
is highly influenced by the availability of cognate hormones in addition to the
recruitment of several transcription co-regulators (Glass & Rosenfeld, 2000; Shang,
Hu, DiRenzo, Lazar, & Brown, 2000). Most of which are believed to influence the rate
of transcription by modifying the chromatin structure as well as facilitating the
hormone receptors communication with the transcription machinery(Glass &
Rosenfeld, 2000; McKenna & O'Malley, 2002).
In addition to these regulatory processes, transcription elongation and RNA
processing are also linked with gene expression control (Auboeuf et al., 2004;
Orphanides & Reinberg, 2000; Zorio & Bentley, 2001). Previous in vivo studies have
indicated a novel role of COBRA1 as a corepressor of the ER-α dependent gene
expression through stalling of RNAPII (S. E. Aiyar et al., 2004). Upon Estrogen
stimulation, COBRA1 along with the other NELF subunits binds to ERα in breast
cancer cells and is recruited to the promoters of ER target genes, resulting in RNAPII
stalling and suppression of the ERα-mediated transcription(S. E. Aiyar et al., 2004).
This regulation of the transcription has introduced a unique level of hormonal gene
regulation which is diverse from most of the known steroid receptors co-regulators
actions(J. Sun et al., 2007).
The majority of nuclear receptors (NR) co-regulators have the ability of binding to
several receptors as well as mediating the regulation of transcription. This capability is

15

mainly explained by the presence of many NR-binding motifs ‘LXXLL’ within their
structures(Heinlein & Chang, 2002; McKenna & O'Malley, 2002). Having this
structural feature, COBRA1 was found to bind to several steroid hormone receptors
with diverse affinity degrees. In fact, COBRA1 was found to bind to the androgen
receptor (AR), progesterone receptor B (PRB) and glucocorticoid receptor (GR).
Among these three nuclear receptors, AR was reported to have the strongest binding
affinity to COBRA1. In fact, through its binding to the ligand binding domain (LBD)
of AR, COBRA1 was found to regulate the AR-dependent transcriptional processes.
In addition to binding to the NELF subunits and steroid hormone receptors,
COBRA1 was also found to interact with the transcription factor activator protein
1(AP-1), a heterodimer composed of c-Fos and c-Jun family proteins (Hess, Angel, &
Schorpp-Kistner, 2004). The role of COBRA1 in regulating the AP-1 transcriptional
activity was investigated by Zhong et al in 2004, where it was proved for the first time
that overexpressing COBRA1 represses the activator protein 1(AP1) transcriptional
activity. On the other hand, reduction of COBRA1 via siRNA enhances the AP-1
transcriptional activity. This action of COBRA1 was attributed by its ability to bind to
both c-Fos and c-Jun family members. Particularly, the interaction with the c-Fos
members is essential for this inhibitory action, where the lack of the c-Fos binding site
in COBRA1 completely stops the inhibitory effect of COBRA1 on the AP1-mediated
transcriptional activity (Zhong et al., 2004). Given that AP-1 is known to be involved
in many biological processes including cell fate and oncogenesis, COBRA1 was
proposed to have a function in regulating these processes through AP-1 signalling.
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1.2.4 Role in Cancer
The role of COBRA1 in cancer was first driven by its identification as a BRCA1interacting nuclear protein, and its potential role in regulating nuclear events such as
transcription, cell cycle, DNA repair and cell proliferation(Zhu et al., 2004). In
addition, the role of COBRA1 in regulating the AP1- mediated transcriptional activity
and ligand-dependant gene expression, which are both involved in cancer development,
has raised the possibility of its involvement in cancer (S. E. Aiyar et al., 2004; J. Sun
et al., 2007; Zhong et al., 2004).
To date, COBRA1 role in the tumorigenesis of breast and gastrointestinal carcinoma
has been investigated and identified. In breast cancer, previous studies have identified
COBRA1 as a tumor suppressor. Upon the identification of its ability to interact with
BRCA1 in 2001, the mRNA and protein levels of COBRA1 were found to be reduced
in different breast cancer cell lines (Zhu et al., 2004). In addition, a physical interaction
between BRCA1 and COBRA1 was observed in these cells, indicating its possible
involvement in the regulation of breast cancer growth (Zhu et al., 2004). Moreover,
COBRA1 was found to physically bind to the ligand binding domain (LBD) of ERα
and inhibits the estrogen-dependent transcription in breast cancer cells (S. E. Aiyar et
al., 2004).
In line with the effect of COBRA1 in the regulation of breast cancer growth, another
study done by Sun et al., (2008) has demonstrated a tumor-suppression role of
COBRA1 in breast cancer. In this study, it was found that COBRA1 expression is
significantly reduced in metastatic breast cancer samples (J. Sun et al., 2008). These
observations go in line with another study that revealed that COBRA1 can regulate the
expression of genes associated with breast cancer progression and metastasis such as
the trefoil factor1 gene (TFF1) (S. E. Aiyar et al., 2004; Smid et al., 2006).
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Contrasting its role in breast cancer, COBRA1 was found to act as an oncogene in
the upper gastrointestinal carcinomas (UGCs). In fact, COBRA1 was found to be
overexpressed in 60% of primary UGG samples compared to normal samples
(McChesney et al., 2006). Unlike breast cancer, COBRA1 overexpression was
accompanied by down regulation of TFFI (McChesney et al., 2006). This contradictory
role of COBRA in breast and gastrointestinal carcinoma is believed to be due to its
interaction with different site-specific transcription factors. Thus, regulating distinct
transcription processes in different cell and tissue types (Adams et al., 2005;
McChesney et al., 2006; J. Sun et al., 2008).
The role of COBRA1 in other cancer types has not been identified yet. However,
it’s worth mentioning that a previous tissue array study has indicated a significant
expression of COBRA1 in the epithelial of many tissues, indicating the possibility of
its involvement in the tumerogenousis in tissues other than breast and upper
gastrointestinal tract (J. Sun et al., 2008). Given the role of COBRA1 in influencing the
alternative splicing pattern of receptor genes, current research is directed towards
identifying cancer-associated alternative splicing patterns of COBRA1-regulated
genes. Moreover, due to its role as a modulator of androgen-dependent transcription in
addition to the importance of androgen in the development of prostate cancer,
COBRA1 was suggested to have a role in the tumorigenesis of prostate cancer.
However, further studies to confirm these notions are required.
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1.2.5 Role in Hepatocellular Carcinoma
In hepatocellular carcinoma, Previous studies have revealed a potential role for
COBRA1 in HCC pathogenesis (Youssef, Shawer, Afify, & Amleh, 2016). In addition,
other studies have established a possible link between COBRA1 and several proteins
known to be involved in tumorigenesis and anti-apoptotic pathways (El Zeneini et al.,
2016). In this study, COBRA1 was knocked-down. As a result, the growth and
migration of HCC cells were significantly decreased. In addition, a decrease in the
expression of the proliferation marker; Ki-67 as well as the anti-apoptotic gene;
survivin was also observed (El Zeneini et al., 2016).
HYPOTHESIS AND SPECIIC OBJECTIVES
The above-mentioned data obtained from ongoing research suggests strongly a positive
role of COBRA1 in the migratory and proliferation potentials of HCC. Therefore, we
hypothesize that COBRA1 overexpression will have a role in both the proliferation and
migration potentials of HCC cells. To address this hypothesis, our study had the
following three objectives:
1. To establish a successful COBRA1-overexpression in the HCC cell line, HepG2.
HepG2 represents a pure cell line of Hepatocellular Carcinoma. It is derived from
a 15-year old Caucasian, American male with early stage HCC (Costantini, Di
Bernardo, Cammarota, Castello, & Colonna, 2013; Fornari et al., 2010; Yie et al.,
2015).
2. To examine the levels of the NELF complex subunits as well as the NELF complexregulated genes, TFF1 and TFF3 following COBRA1 overexpression.
3. To investigate the effect of COBRA1 overexpression on the proliferation and
migration of HepG2 cells as well as the expression of tumorigenesis-related genes.
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CHAPTER 2. MATERIALS AND METHODS

2.1. Cell Culture
The human hepatocellular carcinoma cell line, HepG2, was kindly provided by Dr.
Mehmet Ozturk from the Department of Molecular Biology and Genetics, Bilkent
University, Turkey. The cells were cultured in RPMI 1640 (Lonza, USA) supplemented
with 10% heat-inactivated fetal bovine serum (Invitrogen, USA) and 5% Penicillinstreptomycin antibiotic (Invitrogen, USA). Cells were incubated at 37°C in a
humidified atmosphere of 5% CO2 and used when in the log phase of growth. Cells
were regularly observed by the inverted microscope (Olympus IX70, USA) for their
morphology, growth, lack of any biological contamination and the percentage of
confluence.
2.2. Viable Cell Count
The cells viability was estimated using the trypan blue dye-exclusion method, where
an aliquot of the cells was two-fold diluted using 0.4% w/v trypan blue. 10 ul of the
diluted cell suspension was loaded into the haemocytometer’s chamber. The number
of cells in the chamber’s four outer squares was then counted. To determine the cell
count, the following formula was applied:
[Viable cell count (live cells/ml) = (Number of live counted cells x dilution factor x
10,000) / Total number of counted squares].
2.3. Plasmid constructs
2.3.1 pCMV5-HCOBRA1Plasmid
The pCMV5-HCOBRA1 expression plasmid was generously provided by Dr.Rong
Li, University of Texas Health Science Centre, San Antonio-USA. To generate
pCMV5-HCOBRA-1, EcoRI and SalI enzymes were used to clone the 5`UTR+CDS of
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HCOBRA1+flag to the 4.7 Kb sized pCMV5 vector, resulting in a plasmid of the size
of 6.6 Kb. The plasmid was shipped on a filter paper and recovered by immersing in
TE buffer followed by transforming into Top10 competent bacterial cells.
2.3.2 pCMV5-empty plasmid
In order to be used as a negative control in the transfection process, an empty
pCMV5-plasmid was prepared. Briefly, pCMV5-HCOBRA1 was digested with EcoRI
and SalI enzymes. The empty vector (4.7 fragment) was purified using QIAquick Gel
Extraction Kit. The 5` overhangs resulted from the digestion were blunted by filling in
with the Klenow fragment of DNA polymerase I. One unit of klenow was added per 1
µg of DNA, followed by incubation at 25°C for 15 minutes and heating at 67 °C for 20
minutes. The blunted vector was then re-ligated using T4 DNA ligase. Correct ligation
was confirmed by restriction linearization using BamH1 enzyme as well as the colony
PCR technique. The ligation reaction was then transformed into Top10 competent cells,
and glycerol stocks of the vector were prepared.
2.3.3 pEGFP-N1 Plasmid
The pEGFP-N1expression plasmid was provided by Dr. Ahmed Osman, Ain Shams
University, Egypt. The expression vector was originally purchased from Clontech
(http://www.clontech.com).
2.4. Transformation
In order to have larger amounts of plasmid DNA for further experiments, bacterial
cells were transformed with the acquired plasmids and propagated in bacterial medium
prior to preparation of glycerol stocks and harvesting for DNA.
Top10 competent cells were transformed with the suitable plasmids. 50 µl of the
cells were first thawed on wet-ice. 1-5 µl of the plasmid-DNA were added to the
competent cells and mixed gently. The mixture was left on ice for 30 minutes followed

21

by an immediate heat-shock at a temperature of 42 ºC for 30 seconds. Following this,
900 µl of pre-warmed LB media were added to the mixture. The vial containing the
cells was then incubated at 37 ºC for 1 hour. 50 µl of the transformation mixture were
plated on LB agar plates that contain 100 µg/ µl ampicillin. The plates were then
incubated at 37 ºC overnight. A single colony was selected the next day and placed in
a culture containing 5 ml of LB media with 100 µg/µl ampicillin. Following an
overnight incubation in a 37 ºC shaker, the cells were harvested and the plasmid DNA
was extracted using Mini Prep Kit (Qiagen).
To prepare glycerol stocks, 600 µl of the liquid culture were added to 400 µl of 50%
glycerol and stored at -80 ºC for further use.
2.5. Restriction digestion
Restriction enzymes were used to confirm the identities of the newly obtained
plasmids. EcoR1 and SalI restriction enzymes were used to digest the pCMV5HCOBRA1 vector. EcoRI was used to linearize the pCMV5-COBRA1 and the
pEGFP.N1vectors. SalI was used to linearize the pEGFP.N1vector. BamH1was used
to linearize the pCMV5-empty vector. The digestion reaction was performed in a final
volume of 20 µl, consisting of 15 µl distilled water, 2 µl of 10 X NEBuffer 3.1to a final
concentration of 1X, 0.25 µg of the extracted plasmid DNA and 1 µl of each enzyme.
The linearization reaction was performed in a final volume of 20 µl, consisting of 15
µl distilled water, 2 µl of 10X NEBuffer EcoRI or 10 X NEBuffer 3.1 to a final
concentration of 1X, 0.25 µg of the extracted plasmid DNA and 1.8 µl of EcoRI, SalI
or BamH1 enzyme. The reaction was gently mixed and incubated for 1 hour at 37 ºC.
The undigested plasmids, linearized plasmids and digested plasmids were run on a 1%
agarose gel and visualized using Gel Doc EZ System (Bio-Rad, USA).
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As EcoRI cuts the pCMV5-HCOBRA1 plasmid once at the 0.92 Kb position, a
6.557 Kb fragment will be expected. As SalI enzyme cuts the plasmid once at the 0.968
position, when used together with EcoRI, two bands of the sizes 4.609 Kb and 1.9 Kb
will be expected on the agarose gel. As BamH1 cuts the plasmid once at the 0.98 Kb
position, a 4.657 Kb fragment will be expected. As EcoRI cuts the pEGFP.N1 plasmid
once at the 0.629 Kb position, a 4.733Kb fragment will be expected. As SalI enzyme
cuts the plasmid at 0.639 Kb position, a 4.733 Kb fragment will be expected.
2.6. Colony PCR
The identity of the pCMV5-HCOBRA1 and pCMV5-empty vector was further
confirmed by the colony PCR technique. A single colony obtained following an
overnight culture of pCMV5-HCOBRA1 and/or pCMV5-empty transformed bacterial
cells was suspended in 20 µl distilled water and boiled at 95 ºC. The PCR reaction for
colony analysis was prepared in a final volume of 25 μl consisting of the followings:
2.5 µl of 10X DreamTaq Green Buffer(Thermo Scientific), 0.5 μl dNTPs mix (Thermo
Scientific), 0.2 μl Dream Taq DNA Polymerase (Thermo Scientific), 1 μl of forward
and reverse specific primers, 1 μl of the colony suspension as well as H2O. The PCR
conditions were as follows: initial denaturation at 95ºC for 4 minutes, followed by 32
cycles of (denaturation at 95ºC for 30 seconds, annealing at 59.5ºC for 30 seconds and
extension at 72ºC for 45 seconds) before finishing with a final extension at 72ºC for 7
minutes. The amplified PCR products were run on a 1.5% agarose gel and visualized
using Gel Doc EZ System (Bio-Rad, USA).
2.7. Cell transfection
Transient transfection of HepG2 cells with pCMV5-HCOBRA1 was performed
using the lipofectamine 3000 reagent (Life Technologies) according to the
manufacturer’s protocol. Briefly, HepG2 cells were seeded in six-well culture plates,
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and incubated for 24 hours until reached 70-90% confluence. Before transfection, 3.75
µl of lipofectamine 3000 were added to 125 µl of Opti-MEM reduced serum medium,
and incubated for 5 minutes at room temperature. Meanwhile, 2.5 µg pCMV5HCOBRA1 was diluted in 125 Opti-MEM reduced serum medium and 5 µl of P3000
reagent. Following this, the two dilutions were mixed and incubated for 20 minutes to
allow formation of the complex. The DNA-lipofectamine complexes (250 µl) were then
added to each well of the 6-well plate. Media was changed 8 hours post transfection.
48 hours following transfection, cells were harvested for RNA and protein analysis.
As controls, cells were either left un-transfected (blank) or transfected with an empty
vector (pCMV5-empty vector). The pEGFP.N1 vector was used as a positive control
to determine the transfection efficiency. Forty eight hours following transfection, the
florescent cells were visualized by the Olympus IX70 fluorescence microscope using
the GFP filter set. Likewise, the total number of cells in the same field were visualized
using the bright filter set. Photo-microscopy was done using cellsens imaging software
(Olympus IX70). Cell counts were performed using ImageJ Software (National
Institute of Health, USA, http://www.imagej.nih.gov/ij). The transfection efficiency
was then estimated according to the following formula:
Tansfection efficiency = (florescent cells per field /total number of cells per field)
X 100’
2.8. RNA Extraction
Total RNA was extracted from HepG2 cells using Trizol reagent (Invitrogen, USA)
according to the manufacturer's instructions. The extracted RNA was suspended in
diethlpyrocarbonate –treated (DEPC) water. Following this, the concentration of the
extracted RNA was measured at 260 nm using an UV spectrophotometer (Shimadzu,
Japan).
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2.9. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA (0.5 μg) was reverse transcribed using a Revert Aid First strand cDNA
synthesis Kit (Thermo Scientific, USA). Messenger RNA expressions were determined
using semi-quantitative RT-PCR. The PCR reaction was prepared by mixing the
following reagents: 10X DreamTaq Green Buffer (Thermo Scientific), 10 mmol/L
dNTPs mix) (Thermo Scientific), 1X Dream Taq DNA polymerase (Thermo
Scientific), forward and reverse specific primers and water. β-actin was used as an
internal control. The primers used for the amplification of the genes are listed in Table
(1). PCR amplifications conditions were programmed for 5 minutes at 95°C, followed
by cycles of (denaturation at 95ºC for 30 seconds, annealing at 56ºC-63ºC depending
on the used primers for 30 seconds, extension at 72ºC for 45 seconds) and finishing
with 7 minutes at 72ºC. The amplification process was carried out for a number of
cycles depending on the used primers (Table 1). The PCR products were then separated
on a 1.5% agarose gel and visualized using Gel Doc EZ System (Bio-Rad, USA).

25

Table 1. RT-PCR primer sequences, annealing temperatures, cycle numbers and
amplicon sizes (F: forward primer, R: reverse primer, bp: base pair)

Gene

Primer Sequence

Annealing
Temp.

Cycle
number

Amplicon
size (bp)

B-ACTIN

F: GCAAAGACCTGTACGCCAAC
R: GAGACCAAAAGCCTTCATACATCTC

58°C

27 cycles

777

COBRA1

F: ACATCACCAAGCAGAGGAA
R: GATCCAGCTGTTCCAGCTTC

59.5°C

32 cycles

366

Survivin

F: TTGAATCGCGGGACCCGTTGG
R: CAGAGGCCTCAATCCATGGCA

61˚C

32 cycles

Isoform 1: 477
Isoform 2: 359
Isoform 3: 546

NELF-A

F: GTCGGCAGTGAAGCTCAAGT
R: TTCACACTCACCCACCTTTTCT

60˚C

35 cycles

250

NELFC/D

F: GAAGAAGGAGAGACCCCAGC
R: GTGCCCAAGGCTAGTGTGAT

56˚C

28 cycles

443

F: TGGTGAAGTCAGGAGCCATCAG
R: CGCCGTTCAGGGAATGAATC

63˚C

28 cycles

565

Ki-67

F: CTTTGGGTGCGACTTGACG
R: GTCGACCCCGCTCCTTTT

60˚C

28 cycles

199

TFF1

F: TTTGGAGCAGAGAGGAGGCAATGG
R: TGGTATTAGGATAGAAGCACCAGGG

60˚C

32 cycles

240

TFF3

F: GTGCCAGCCAAGGACAG
R: CGTTAAGACATCAGGCTCCAG

58˚C

35 cycles

302

NELF-E

2.10. Western blot Analysis
Total cell lysates were prepared using ice-cold PBS and laemmli lysis buffer
supplemented with 1X Halt Protease Inhibitor Cocktail (Thermo Scientific, USA). The
concentrations of proteins were determined using Thermo Scientific Pierce BCA
protein kit (Pierce Biotechnology, USA) according to the manufacturer’s protocol.
Equivalent amounts (20-50 μg) of proteins diluted in a lysis buffer were mixed with
the loading dye and separated on a 12 % SDS-PAGE. Consequently, they were blotted to a
nitrocellulose membrane. Following blocking with 5% non-fat dry milk in 1X PBST
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(0.01% Tween-20 in PBS) at room temperature for 1 hour, the membrane was
incubated with the primary antibody at 4 ºC overnight. Following three times washing (5
minutes each) with the wash solution (1 X PBS and 0.1% Tween), the membrane was
incubated with alkaline phosphatase conjugated secondary antibody (either goat antirabbit IgG (KPL) or goat anti-mouse (KPL) diluted as 1:20,000 in 5% non-fat milk) at
RT for two hours, and washed 3 times with the wash solution. For detection, the membrane
was incubated with the chemiluminescent PhosphoGLO Substrate (55-60-04, KPL)
for 5 minutes prior to exposing it to an X-ray film in the dark. Signals were then
detected by developing the film in developer and fixer solutions. Anti-β-tubulin
(Sigma, T7816) (1:20,000 in 5% non-fat dry milk), anti-COBRA1 (Abcam, ab167401)
(1:1000 in 5% non-fat dry milk) and anti-NELF-E (Abcam ab170104) (1:1000 in 5%
non-fat dry milk) were used as primary antibodies in this study.
In order to use the same membrane for detection of other proteins, the membranes
were incubated in the stripping buffer (0.5 M Tris-HCl,10% SDS and betamercaptoethanol) at 55 °C for 30 minute prior to excessive washing with water to
remove any beta-mercaptoethanol traces. The membranes were then blocked with 5%
non-fat dry milk in 1X PBST before incubating with another primary antibody.
2.11. Wound-healing assay
The wound-healing assay was used to evaluate the migratory potentials of HepG2
cells. Forty-eight hours post transfection, the cells monolayer was scraped by a yellow
pipette-tip creating a cross-shaped wound. The cells were then washed with PBS to
remove any detached cells and incubated for 24 hours. Images of the same wound
location were obtained at both the (0 hr) and the (24 hr) times. The open wound area
was analysed using the TScratch software (Gebäck, Schulz, Koumoutsakos, &
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Detmar, 2009), and the percentage wound closure was calculated according to the
formula:
Percentage wound closure = [(wound area 0 hr-wound area 24 hr)/ wound area 0hr] x
100
2.12. Statistical analysis
For PCR and Western blot analysis, the bands intensities were quantified and
normalized per the used internal control using Image J software (National Institute of
Health, USA, http://www.imagej.nih.gov/ij). Relative differences in gene expression
are described as fold change to the empty vector-transfected cells.
All statistical analysis were performed using GraphPad Prism 7.0 (GraphPad, San
Diego California USA, http://www.graphpad.com/). All the data represent the average
± standard deviation (SD) from three independent experiments. When comparison was
made between two different groups, statistical significance was determined using an
unpaired student's t-test (two-tailed). One-way ANOVA (Analysis of Variance),
followed by a Bonferroni post-test was used to determine the statistical significance
among multiple different experimental groups. In all analyses, P < 0.05 was considered
statistically significant (* p <0.05; ** p value <0.01; *** p value <0.001).
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CHAPTER 3. RESULTS

3.1. Confirmation of plasmids identities
Before using the plasmids in the transfection assays, their identities were confirmed
by performing restriction digests on the plasmids and comparing the obtained
fragments sizes with those expected from the corresponding plasmid restriction map.
The pcMV5-HCOBRA1 plasmid restriction digestion by both EcoRI and SalI resulted
in two bands of the sizes 4.609 and 1.9 Kb as expected from the restriction map. EcoRI
digestion resulted in a linearized plasmid with the expected band size of 6.6 Kb (Figure
1A). The pCMV5-empty plasmid restriction digestion by BamH1 resulted in a
linearized plasmid with the expected band size of 4.657 Kb (Figure 1B). The
pEGFP.N1 plasmid restriction digestion by EcoRI resulted in a linearized plasmid with
the expected band size of 4.7 Kb. As such, pEGFP.N1 plasmid restriction digestion by
SalI resulted in a linearized plasmid with the expected band size of 4.7 Kb (Figure 1C).
The pCMV5-HCOBRA1 and the pCMV5-empty plasmids identities were further
confirmed through colony PCR. Amplification of the colony obtained from the
pCMV5-HCOBRA1 transformed cells resulted in an amplicon of the expected size of
366 bp. On the other hand, amplification of the colony obtained from pCMV5-empty
plasmid resulted in no bands (Figure 1D).
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Figure 1. Confirmation of plasmids identities
Lane 1 shows GeneRuler 1 Kb ladder (A) pCMV5-HCOBRA1 restriction digests: Lane 2 shows the
uncut plasmid. Lane 3 shows an EcoRI digestion resulting in a band of the approximate size of 6.6 Kb.
Lane 4 shows EcoRI & Sall digestion resulting in two bands of the sizes of 4.609 and 1.9 Kb. (B) The
pCMV5-empty plasmid restriction digests: Lane 2 shows the uncut plasmid. Lane 3 shows BamH1
digestion resulting in a band of the size of 4.657 Kb. (C) pEGFP-N1 restriction digests: Lane 2 shows
the uncut plasmid. Lane 3 shows EcoRI digestion resulting a band of the size of 4.7 Kb. Lane 4 shows
SalI digestion resulting in a band of the size of 4.7 Kb. (D) Colony PCR: colonies obtained from pCMV5HCOBRA1 transformed cells resulted in a 366 bp amplicon (Lane 2). Colonies obtained from pCMV5empty plasmid resulted in no bands.

3.2. Optimal protocol for HepG2 cells transfection
To determine if lipofectamine 3000 is effective in overexpressing of COBRA1 in
HepG2 cells, we first optimized the best protocol to be used in transfecting HepG2
cells. A series of optimizations were conducted per the manufacturer’s
recommendations. We first compared the transfection efficiency between both the
reverse and forward transfections. Then, we attempted to determine the most suitable
lipofectamine volume to be used in the transfection. Finally, we examined whether
increasing the incubation time of the cells following transfection can further enhance
the transfection efficiency.
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3.2.1. Reverse transfection versus Forward transfection
Both reverse and forward transfections were used to overexpress COBRA1 in
HepG2 cells. Usually, when using the forward transfection, cells are seeded 24 hours
prior to transfection. On the other hand, in the reverse transfection, the cells are added
directly to the transfection mix(Erfle et al., 2007).
Overexpression efficiency was compared between both reverse and forward
transfections based on the percentage of the green florescent (pEGFP.N1+) cells. As
shown in figure 2 A, the forward transfection resulted in a higher efficiency (45%) than
that observed with the reverse transfection (20%). Accordingly, the forward
transfection was used in the subsequent transfection experiments.
3.2.2. Lipofectamine volume
Two lipofectamine volumes (3.75 μL and 7.5 μL) were used to form lipofectamineDNA complexes as recommended by the supplier. Transfection using 3.75 μL
lipofectamine resulted in a transfection efficiency of 45 %. On the other hand,
transfection using 7.5 μL lipofectamine resulted in a transfection efficiency of 30%.
Using this volume, detrimental cytotoxicity was observed following the transfection
when compared to un-transfected cells (Figure 2 B).
Beside the GFP expression, COBRA1 overexpression was also compared between
the two tested volumes. As shown in figure 2 C&E, cells transfected with 3.75 μL of
lipofectamine showed the highest overexpression on both the mRNA steady state
expression and protein levels. Due to its higher transfection efficiency as well as low
cytotoxic effects, the 3.75 μL lipofectamine was used in the subsequent transfections.
3.2.3. Incubation duration
We further optimized our protocol by examining the effect of increasing the
incubation duration of cells following transfection. Transfection efficiency was
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analysed at both 24 hr and 48 hr post-transfection. As shown in figure 2 E, incubating
the cells for 48 hours resulted in a higher transfection efficiency (60%), compared to
(45%) observed after 24 hours incubation. Accordingly, cells were incubated for 48
hours in the following transfections.
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Figure 2. Optimization of COBRA1 transfection in HepG2 cells
The optimization of the transfection process is based on the percentage of the green florescent (pEGFPN1+) cells, RT-PCR and western blot analysis (A) Comparison between the transfection efficiency
(pEGFP-N1+ cells) of reverse and forward transfection 24 hrs post transfection. The forward transfection
resulted in an efficiency of 45% compared to 20% observed with the reverse transfection. (B)
Lipofectamine volume. Two lipofectamine volumes of (3.75µl and 7.5 µl) were used and compared to
their transfection efficiency based on the green florescent (pEGFP-N1+) cells. 45% transfection
efficiency was obtained by using 3.75 µl lipofectamine in comparison to 30% obtained with 7.5 µl
lipofectamine. (C) Comparison between the two lipofectamine volumes based on western blot analysis.
(D) Comparison between the two lipofectamine volumes based on COBRA1 mRNA expression using
semi-quantitative RT-PCR. The bands intensities in (C) and (D) were measured and normalized to their
corresponding bands of the internal control (β-actin, β-tubulin) using image J software. (E) Incubation
duration. Transfection efficiency was analysed at both 24 hr and 48 hrs post transfection and compared
based on the green florescent (pEGFP-N1+) cells. Incubating the cells for 48 hrs resulted in a higher
transfection efficiency (60%) compared to (45%) observed after 24 hrs incubation.
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3.3. COBRA1 transfection efficiency and effect on cells morphology
Upon using lipofectamine 3000 in the transfection, cells transfected with the pCM
V5-HCOBRA1 plasmid showed a significant higher COBRA1 protein expression (P
<0.001) compared to the control groups (Figure 3 A). Similarly, COBRA1 mRNA
steady state expression was also significantly increased compared to the control groups
as evidenced by the semi-quantitative RT-PCR (P<0.001) (Figure 3B).
To determine whether COBRA1 overexpression alters the morphology pattern of
HepG2 cells, photos of the pCMV5-HCOBRA1- transfected cells were compared to
those obtained from the other control groups (pCMV5-empty-transfected, pEGFP.N1
transfected and un-transfected cells). No significant difference in the cell morphology
among all the tested groups was observed, indicating that COBRA1 doesn’t induce any
morphological changes in HepG2 cells (Figure 4).
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Figure 3. COBRA1 significantly overexpressed at both mRNA and protein levels
(A) Western blot analysis of COBRA1 protein expression in pCMV5-HCOBRA1-transfected cells,
relative to pCMV5-empty vector-transfected cells (B) Semi-quantitative RT-PCR analysis of COBRA1
mRNA steady state expression in pCMV5-HCOBRA1- transfected cells, relative to pCMV5-emptytransfected cells. A significant overexpression of COBRA1 on both mRNA and protein levels was
observed. The intensities of the bands in (A) and (B) were measured then normalized to the loading
control by image J software. Data represents the average ± SD of three independent experiments.
Statistically significant at *** p < 0.001. (One-way ANOVA, Bonferonni’s post-test).

Figure 4. The morphology pattern of HepG2 cells following COBRA1 overexpression.
No changes on the cells morphology were observed following COBRA1 overexpression. Photos were
obtained using phase contrast at 40X magnification.
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3.4. mRNA and protein levels of the NELF subunits following COBRA1
overexpression
To determine whether COBRA1 overexpression influences the expression of the
other NELF subunits, the mRNA levels of NELF-A, NELF-C/D and NELF-E were
compared between COBRA1 transfected cells and the negative controls using RTPCR. As shown in figure 5 A, the mRNA levels of the three subunits showed
comparable levels with no statistically significant difference noticed among them (P>
0.05) (Figure 5A). Similarly, when examined by western blot analysis, no significant
difference in NELF-E protein levels was noticed in pCMV5-HCOBRA1-transfected
cells compared to the control groups (p > 0.05) (Figure 5B).

Figure 5. The expression of NELF-A, NELFC/D and NELF-E subunits upon COBRA1
overexpression
HepG2 cells were transfected with pCMV5-empty vector, pCMV5-HCOBRA1, pEGFP-N1 or left untransfected. 48 hrs post transfection, cells were harvested and analysed for mRNA expressions of NELFA, NELF-C/D and NELF-E by the semi quantitative RT-PCR. (B) HepG2 cells were transfected with
pCMV5-empty vector, pCMV5-HCOBRA1 or left un-transfected. 48 hrs post transfection, cells were
harvested and analysed for the protein levels of NELF-E by western blot analysis. The intensities of the
bands in (A) and (B) were measured then normalized to the loading control by image J software. Data
represents the average ± SD of three independent experiments (one-way ANOVA, Bonferonni’s posttest) (P>0.05).
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3.5. TFF1 and TFF3 mRNA levels following COBRA1 overexpression
Both TFF1 and TFF3 are known to be regulated by the NELF complex (S. Aiyar,
Blair, Hopkinson, Bekiranov, & Li, 2007; S. E. Aiyar et al., 2004; Kininis, Isaacs, Core,
Hah, & Kraus, 2009). To determine the effect of overexpressing COBRA1 on the levels
of TFF1 and TFF3, the mRNA steady state levels of these genes were compared
between the COBRA1 transfected cells and the non-transfected cells. Notably, no
statistically significant difference in the mRNA levels of both TFF1 and TFF3 was
noticed among all the groups (Figure 6).

Figure 6. TFF1 and TFF3 expressions following COBRA1 overexpression
(A) Semi-quantitative RT-PCR analysis of TFF1 mRNA levels in pCMV5-empty-transfected cells,
pCMV5-HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells and un-transfected cells. (B) Semiquantitative RT-PCR analysis of TFF3 mRNA levels in pCMV5-empty-transfected cells, pCMV5HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells and un-transfected cells. The intensities of the
bands in (A) and (B) were measured then normalized to the loading control by image J software. Data
represents the average ± SD of three independent experiments. (One-way ANOVA, Bonferonni’s posttest). (P>0.05).
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3.6. COBRA1 overexpression effect on the proliferation potential of HepG2 cells
To investigate if overexpressing COBRA1 can promote the cellular proliferation,
the growth of cells transfected with either pCMV5-COBRA1 or pCMV5-empty vector
was monitored for 4 days following transfection.
COBRA1 transfected cells showed comparable proliferation rate compared to that
of those transfected with the empty vector (Figure 7A). These results suggested that
COBRA1 overexpression doesn’t have a proliferation endorsing role in HepG2 cells.
To confirm this notion, we examined the expression of the proliferation marker, ki-67
following COBRA1 overexpression. Ki-67 is known to be associated with cell
proliferation. The presence of this protein in the nuclei of cells in the active phases of
the cell cycle (G1, S, G2, and mitosis), in addition to its absence from the resting phase
(G0), makes of it a good indicator of the cells growth and proliferation (Gerdes &
Scholzen, 2000). No significant difference in ki-67 mRNA levels was observed in
COBRA1-trnasfected cells when compared to the control cells as evidenced by semiquantitative RT-PCR (P >0.05) (Figure 7 B).
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Figure 7. The proliferation potential of HepG2 cells following COBRA1 overexpression
(A) Cell growth curve representing the growth of cells transfected with either pCMV5-HCOBRA1 or
pCMV5-empty vector. HepG2 cells were transfected with the pCMV5-empty or pCMV5-HCOBRA1
vector, harvested at 24, 48, 72 and 96 hrs post transfection, and counted using the trypan blue dyeexclusion method. Data represents the average ± SD of three independent experiments (two-way
ANOVA, Bonferonni’s post-test) (B) Semi-quantitative RT-PCR analysis of Ki-67 mRNA expression
in pCMV5-empty-transfected cells, pCMV5-HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells
and un-transfected cells. The intensities of the bands were measured then normalized to the loading
control by image J software. Data represents the average ± SD of three independent experiments. (Oneway ANOVA, Bonferonni’s post-test) (P>0.05).

3.7. COBRA1 Overexpression effect on the migratory potential of HepG2 cells
To examine if overexpressing COBRA1 can enhance the migration of HepG2 cells,
the wound-healing assay was applied. Both pCMV5-HCOBRA1 and pCMV5-empty
plasmids-transfected cells were compared according to their migration rates. Cells
transfected with pCMV5-HCOBRA1 closed the scratch wounds at a higher rate than
the cells transfected with the pCMV5-empty plasmid. However, the wound closure of
both groups showed no statistically significant difference (P>0.05), with a wound
closure percentage of 11.3% obtained for pCMV5-empty plasmid-transfected cells and
15.5 % for pCMV5-HCOBRA1plasmid-transfected cells (Figure 8).

39

Figure 8. The migratory potential of HepG2 cells following COBRA1 overexpression.
The wound healing assay was used to analyse the migration rate of HepG2 cells following COBRA1
overexpression (A) Images of the wound areas taken at both 0 and 24 hrs times using phase contrast at
10X magnification (B) The percentage of wound closure in pCMV5-HCOBRA1 transfected cells versus
pCMV5-empty transfected cells. The open areas were measured using TScratch software followed by
calculation of the percentage of wound closure. Data represents the average ± SD of three independent
experiments. (Student t-test, two-tailed) (P>0.05).

3.8. COBRA1 Overexpression effect on the survivin gene expression
To determine if overexpressing COBRA-1 could affect the expression of genes
known to be deregulated in cancer, RT-PCR was carried out to examine the mRNA
expression of the survivin gene following COBRA-1 overexpression. The survivin
gene is known to be deregulated in cancer, and was shown to play key roles in the
survival and proliferation of cancer cells (Fukuda & Pelus, 2006). As shown in Figure
9, upon COBRA1 overexpression, no statistically significant difference in the levels of
the 3 survivin transcripts (survivin-2B, survivin-deltaex3 and the wild type survivin)
was noticed compared to the control groups ( P>0.05).
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Figure 9. survivin mRNA expression following COBRA1 overexpression.
HepG2 cells were transfected with pCMV5-empty, pCMV5-HCOBRA, pEGFP-N1 or left untransfected. 48 hrs post transfection, total RNA was extracted and analysed for survivin mRNA
expressions using semi quantitative RT-PCR. The intensities of the bands were measured then
normalized to the loading control by image J software. Data represents the average ± SD of three
independent experiments. (One-way ANOVA).
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CHAPTER 4. DISCUSSION

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related
deaths worldwide, accounting for around 746,000 deaths annually(Flores & Marrero,
2014). Despite the improvements in HCC therapy, almost 80% of the patients were
reported to proceed to advanced stages with poor prognosis(C. Sun et al., 2013; Yin et
al., 2012). Therefore, identifying the molecular mechanisms and biomarkers involved
in HCC pathogenesis is essential for a better management of the disease.
One of the biomarkers that was shown to be involved in HCC is Cofactor of BRCA1
(COBRA1). Previous studies have demonstrated a potential role for COBRA1 in HCC
pathogenesis (Youssef et al., 2016), and established a conceivable link between
COBRA1 and several proteins known to be involved in tumorigenesis including cell
proliferation and anti-apoptotic pathways (ElZeneini et al., 2016). In the current study,
we extended the previous studies by elucidating the link between COBRA-1
overexpression and HCC tumerogenesis.
4.1. Co-dependent stability of the NELF subunits
The multi-subunit negative elongation factor (NELF) complex consists of four
subunits (NELF-A, NELF-B, NELF-C/D and NELF-E). It was reported that all of the
four subunits are essential for the formation of the functional complex. Along with
NELF C/D, NELF-B (COBRA1) acts as a core of the NELF complex to bring both
NELF-A and NELF-E together, resulting in a functional complex (S. E. Aiyar et al.,
2004; Narita et al., 2003). This explains the interdependent manner by which the NELF
complex works. In fact, several studies have previously reported a simultaneous
recruitment of the NELF subunits upon the binding of COBRA-1 to its ER-α regulated
target genes(S. E. Aiyar et al., 2004).
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Our RT-PCR analysis results showed comparable mRNA expressions of the NELF
subunits following COBRA1 overexpression. These results correlates with the
previously suggested involvement of post transcriptional mechanisms in the regulation
of the NELF complex interdependent expression(J. Sun et al., 2008).
Following COBRA1 overexpression, the protein levels of NELF-E showed similar
expressions with those observed in the control groups. These results are supported by
another study, in which ectopic expression of COBRA-1 in T47D breast cancer cells
resulted in an increase in the protein levels of COBRA1, with no change observed in
the expression of the other NELF subunits(J. Sun et al., 2008). These findings indicate
the tight control that governs the stability of the NELF complex under normal cellular
perspectives.
In light with the previously reported co-dependent regulation of the NELF complex,
previous studies have reported a similar expression of different NELF subunits in the
same cancer type. This was reported in breast cancer, where both NELF-B and NELFC/D were found to have decreased levels in the advanced breast cancer cells(J. Sun et
al., 2008). This pattern was also observed in another study, in which both NELF-E and
NELF-B were reported to be associated with the tumorigeneses of gastrointestinal
carcinoma (McChesney et al., 2006). Hence, it would be of interest to examine the roles
of different NELF subunits in HCC development.
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4.2. Trefoil factors (TFF1 & TFF3) expressions relative to COBRA1
overexpression
Trefoil factor family (TFF) members, TFF1 (pS2), TFF2 (SP) and TFF3 (ITF) are
small mucin associated proteins that are highly conserved and tandemly clustered
within a region of 55 kb on the human chromosome 21(Terada, Sakagami, Tabuchi, &
MAEDA, 2001). They are normally expressed in the upper gastrointestinal tract. In
fact, several studies have indicated the involvement of the trefoil factor family (TFF)
genes in the gastrointestinal tract repair and defence mechanisms(Taupin, Kinoshita, &
Podolsky, 2000; Terada et al., 2001).
It was reported that both TFF1 and TFF3 are regulated by the NELF complex (S.
Aiyar et al., 2007; S. E. Aiyar et al., 2004). In fact, previous studies have indicated that
NELF-B (COBRA1) overexpression negatively regulates the expression of these genes
(S. Aiyar et al., 2007; McChesney et al., 2006). Our findings showed a comparable
mRNA levels of both TFF1 and TFF3 between COBRA1-transfected cells and nontransfected cells. In this regard, it is vital to point out the functional entity by which the
NELF complex modulate the gene expression. Previously, it was reported that
COBRA1 mediated repression of ER-α controlled genes is dependent on the presence
of other NELF subunits (S. E. Aiyar et al., 2004). Our results didn’t reveal an increase
in the expression of the other NELF subunits upon COBRA1 overexpression. This
suggests that COBRA1 mediated suppression of TFF1 and TFF3 expression is
dependent on the expression of the other NELF subunits. Thus, we speculate that
overexpressing the other NELF subunits is likely to significantly affect TFF1 and TFF3
genes expression.
Since there are many transcription-binding sites in the promoters of both TFF1 and
TFF3 genes, it is also possible that the expression of these genes is influenced by other
transcription factors beside the NELF complex. This notion is supported by another
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study done on UGC cells. In this study, site-directed mutagenesis of the AP-1 complex
binding sites, to which COBRA1 binds and controls the expression of TFF1, didn’t
alter the expression of TFF1, indicating that TFF1 expression regulation is not
exclusive to COBRA1 (McChesney et al., 2006). Furthermore, it is crucial to mention
that in hepatic cancer, the regulation of TFF1 expression was reported to be mediated
by estrogen stimulation (Barkhem, Haldosén, Gustafsson, & Nilsson, 2002; Jakacka et
al., 2001). In fact, this regulation depends on the interaction between both the ER and
the AP-1 complex. Thus, it is possible that COBRA1 regulation of TFF1 is dependent
on both estrogen stimulation and AP-1 complex. Accordingly, we hypothesize that,
because under the applied experimental conditions, estrogen was at its basal levels,
COBRA1 regulation of TFF1 expression was altered, leading to the observed results.
However, in order to confirm this notion, further studies should investigate whether
estrogen treatment will enhance COBRA1 control of TFF expression.
4.3. COBRA-1 overexpression effect on the proliferation potential of HepG2 cells
One of the essential traits of cancer cells is their ability to sustain chronic
proliferation. Hence, proliferation is considered as one of the main trademarks of
cancer (Hanahan & Weinberg, 2011). Previously, COBRA1 involvement in the
proliferation of different cancer types was reported. In breast cancer, a significant
reduction of the proliferation of breast cancer cells was noticed following COBRA1
Overexpression (S. E. Aiyar et al., 2004). In addition, the role of COBRA1 in ovarian
cancer proliferation was reported. Pohl et al, 2005 have reported a noteworthy decrease
in the proliferation of ovarian cancer cells upon the inactivation of the Ras/MAPK
pathway. Being identified as one of the targets of this oncogenic pathway, COBRA1
expression was also significantly downregulated (>3-fold)(Pohl et al., 2005).
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Our results haven’t indicated any significant role of COBRA1 overexpression in
enhancing the proliferation of HepG2 cells, as evidenced by both the cell growth and
the ki-67 mRNA expression. These findings might appear somewhat unexpected, given
that our group has previously demonstrated a significant decrease of HepG2 cells
proliferation following COBRA1 knock-down (El Zeneini, 2016). This is most likely
explained by the tight regulation of the NELF complex. In fact, previous studies have
demonstrated an interdependent regulation of the NELF subunits, where a knockdown
of any of the NELF subunits results in a co-depletion of the other NELF subunits(Narita
et al., 2007; J. Sun et al., 2008). Thus, it is possible that upon knocking down NELFB, the proper formation of the NELF complex was hindered, resulting in an altered
function of the complex and leading to the observed effect on the cells proliferation.
This raises the possibility that COBRA1 role in the proliferation is dependent on its
cooperation with the other NELF subunits, and that overexpressing NELF B is only
part of the process of promoting the cells proliferation. Thus, it is conceivable that
overexpressing the other NELF subunits would enhance the proliferation-activation
ability of COBRA1. In fact, previous studies done on proteins that function within
complexes, have indicated the importance of the assembly of all the complex subunits
for a proper function of the protein. Wang et al. (2014) reported a similar proliferative
phenotype upon both the knock-down and overexpression of one of the three subunits
of the SR protein-specific kinase (SRPK) complex. This similar phenotype was
explained by the improper assembly of the complex that has resulted in both
cases(Wang et al., 2014). Taken together, our data support the notion that COBRA1
overexpression alone is inadequate to promote HepG2 cells proliferation.
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It is also worth pointing out that other regulatory pathways might be involved in
COBRA1 regulation of the expression of proliferation markers like Ki-67. Nonetheless,
further examinations are required before a conclusion could be drawn here.
4.4. COBRA1 overexpression effect on the migratory potential of HepG2 cells
Another fundamental trait of cancer cells is their ability to migrate from the primary
tumour to other parts of the body, providing by this a good indicator of cancer
progression and metastasis. Thus, studying the migratory potential of cancer cells is
usually carried out to obtain a clear picture of the state of cancer progression and
prognosis (Hanahan & Weinberg, 2011).
The role of COBRA1 in the migration was previously shown in many cancer types
including breast cancer. Sun et al, 2008 have reported a significant low levels in the
advanced breast cancer cell lines, suggesting a strong association with metastatic breast
cancer. These results go in line with the established role of COBRA-1 as a tumor
suppressor in breast cancer(J. Sun et al., 2008).
Here, the wound-healing assay was carried out to investigate COBRA1
overexpression role in the migratory potential of HepG2 cells. Our results showed
comparable migratory ability of COBRA1-transfected cells with that observed with the
empty plasmid-transfected cells. These results oppose those made previously by our
group, in which COBRA1- knockdown was found to significantly decrease the
migratory potential of HepG2 cells (El Zeneini, 2016). This could be explained by the
previously mentioned tight regulation of the NELF complex, which is likely to function
properly within an interdependent manner. Thus, overexpression of COBRA1 alone is
not enough to induce the migration of the cells.
It is crucial to point out that our study was done using HepG2 cells, which represent
early stages of HCC. Given that the migratory potential of cancer cells indicates the
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metastasis and progression state of cancer, it will be worthwhile to include more cells
that represent advanced stages of HCC. In this regard, it is worth mentioning that
previously, our group have reported a higher migratory ability of the advanced stageHCC cells; SNU-449 compared to HepG2 cells(Youssef et al., 2016).
4.5. COBRA1 overexpression effect on the mRNA expression of survivin
survivin, one of the members of the inhibitor of apoptosis family (IAP), is known to
have high expression levels in cancer compared to normal tissues (Ambrosini, Adida,
& Altieri, 1997; Jaiswal, Goel, & Mittal, 2015). The high expression of survivin in
cancer is mainly due to its anti-apoptotic activity as well as its involvement in the cell
cycle progression. In fact, the expression of survivin is cell cycle-dependant. It has
weak expression at the G1 phase, multiplied by 6 in the S phase and exceeding 40 in
the G2/M phase (Boidot, Végran, & Lizard-Nacol, 2014).
survivin is encoded by BIRC5, a 14.5 Kb gene that consists of 3 introns and 4 exons
located in chromosome 17 (Altieri, 2003; Ambrosini et al., 1997). Beside encoding
survivin, BIRC5 encodes four additional splice variants (survivin-2b, survivin-ΔEx3,
survivin-3b and survivin-2a), resulting in variants with different functions (Caldas,
Honsey, & Altura, 2005; Mahotka, Wenzel, Springer, Gabbert, & Gerharz, 1999). Until
now, only WT survivin, survivin-ΔEx3 and survivin-2b functions have been identified.
Both WT survivin and survivin-ΔEx3 were reported to have anti-apoptotic activity, In
contrast, survivin-2b was found to have a pro-apoptotic activity (Conway et al., 2000).
While WT survivin was found to have a role in the cell cycle regulation, both survivin2b and survivin-ΔEx3 weren’t found to have such a role (Noton et al., 2006).
Our findings indicate that all of the three variants of survivin were detected, with a
dominant expression observed in the WT survivin. These results are consistent with a
previous publication, in which the WT survivin was the dominant mRNA transcript
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among the other variants in HCC (Kannangai, Wang, Liu, Sahin, & Torbenson, 2005).
In fact, this pattern of expression was also observed in other cancer types such as
stomach carcinoma as well as cervical cancer(Krieg et al., 2002; Li, 2003).
Previously, our group has demonstrated a suppression of the expression of survivin
upon COBRA1 silencing. Here, our findings didn’t demonstrate any significant
difference in the expression of survivin among all the tested groups. In this regard, it is
valuable to point out that the activation of survivin is mediated by several transcription
factors such as STAT3, KLF5 and DEC1(Boidot et al., 2014). In addition to these
transcription factors, many signalling pathways were found to be involved in the
regulation of survivin expression. Among these are the Phosphoinositide 3kinase(PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway
(Dan et al., 2004). In fact, these regulators are activated by different stimuli. For
instance, it was reported that the treatment of the SK-BR-3 breast cancer cells with
EGF results in induction of the MAPK pathway, increasing by this the expression of
survivin (Peng et al., 2006). Thus, it is possible that COBRA1 regulation of survivin is
mediated by several stimuli. Given this, we speculate that treating the cells with certain
stimuli might induce COBRA1 regulation of survivin. Also, it would be of value to do
a microarray analysis to identify COBRA1- regulated genes and specify their relation
to survivin regulatory pathways.
In light with the established notion that the expression of survivin is correlated with
higher tumor grades(Takashima et al., 2005), it will be interesting to examine COBRA1
effect on the survivin gene using advanced stages- HCC cells. It is also worth
mentioning that there is an increasing evidence suggesting the involvement of posttranscriptional pathways in regulating the expression of survivin (Li, 2003). Thus, it is
possible that detecting survivin on the protein level might lead to more valuable results.
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CONCLUSION

As far as we know, this is the first study to examine the role of COBRA1
overexpression in HCC. In summary, our findings showed that COBRA1
overexpression didn’t alter the expression of the other NELF subunits, indicating a tight
regulation of the NELF complex under normal cellular circumstances.
The insignificant effect of COBRA1 overexpression on the expression levels of both
TFF1 and TFF3 supports the involvement of the other NELF subunits in this regulation,
and raises the possibility of the contribution of other transcription factors and
regulatory pathways as well.
Furthermore, our findings didn’t reveal a significant role of COBRA1
overexpression on the proliferation and migration rates of HepG2 cells. These results
suggest that COBRA1 role in mediating the growth and migration of HCC cells is
dependent on the expression of the other NELF subunits, indicating the functional
entity by which the NELF complex work.
Taken together, this study might serve as a base for further investigation of the role
of the NELF complex in the tumorigenesis of HCC.
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FUTURE DIRECTIONS

This study was limited by testing one type of HCC cells. Hence, in order to gain a
complete picture of the role of COBRA1 in HCC, it will be of value to include more
cells that represent different stages of HCC. In addition, analysing the cell cycle
distribution as well as the apoptotic index will give more insight about the molecular
mechanisms by which COBRA1 overexpression affect HCC. Moreover, Microarray
analysis of COBRA1-regulated genes in HCC will assist in determining the regulatory
pathways by which COBRA1 control HCC.
Under the applied experimental conditions, the GFP-expressing vector used to
determine the transfection efficiency was separate from the COBRA1-expressing
vector. Thus, it is recommended to clone COBRA1 into the GFP-expressing vector to
gain a more reliable view of the transfection efficiency.
In light of the observation of the importance of the expression of all the NELF
subunits in inducing the function of COBRA1, it will be worthy to examine the effect
of overexpressing the other NELF subunits beside COBRA1 on both of the growth and
migration of HCC cells.
To further investigate the role of COBRA1 in the tumorigenesis of HCC, it will be
of interest in the future to include invivo experiments.
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